Diaceutics (LON:DXRX) Hits New 52-Week High - What's Next?

Key Points

• Shares of Diaceutics PLC (LON:DXRX) reached a new 52-week high of GBX 167 ($2.25) during Tuesday's trading, indicating strong market interest.
• Analysts have set a consensus target price of GBX 175 for Diaceutics, with recommendations ranging from a "buy" to "outperform" from various research firms.
• Despite its recent stock performance, Diaceutics reported a negative net margin of 10.90% and a negative return on equity of 7.15% in its latest earnings results.

Shares of Diaceutics PLC (LON:DXRX - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as GBX 167 ($2.25) and last traded at GBX 162 ($2.18), with a volume of 78673 shares trading hands. The stock had previously closed at GBX 165 ($2.22).

Analysts Set New Price Targets

A number of research firms have commented on DXRX. Canaccord Genuity Group reiterated a "buy" rating and issued a GBX 180 price target on shares of Diaceutics in a research note on Tuesday, July 22nd. Royal Bank Of Canada cut their target price on shares of Diaceutics from GBX 195 to GBX 185 and set an "outperform" rating for the company in a report on Thursday, July 10th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of GBX 175.

Diaceutics Stock Performance

The firm has a 50 day moving average price of GBX 144.52 and a 200-day moving average price of GBX 130.20. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.85 and a quick ratio of 9.92. The firm has a market capitalization of £137.08 million, a price-to-earnings ratio of -9,000.00 and a beta of 0.58.

Diaceutics (LON:DXRX - Get Free Report) last posted its earnings results on Tuesday, September 23rd. The company reported GBX (2.84) EPS for the quarter. Diaceutics had a negative net margin of 10.90% and a negative return on equity of 7.15%. As a group, sell-side analysts expect that Diaceutics PLC will post 1.0107919 earnings per share for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.